Get the Stockscreener App
3.13
6.01%
-0.20
Pre-market:
3.21
0.08
+2.56%
Alvotech stock is traded at $3.13, with a volume of 1.13M.
It is down -6.01% in the last 24 hours and down -23.84% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$3.33
Open:
$3.28
24h Volume:
1.13M
Relative Volume:
2.07
Market Cap:
$975.31M
Revenue:
$548.10M
Net Income/Loss:
$69.50M
P/E Ratio:
13.59
EPS:
0.2303
Net Cash Flow:
$-137.90M
1W Performance:
-18.06%
1M Performance:
-23.84%
6M Performance:
-63.52%
1Y Performance:
-72.92%
1-Day Range:
$3.03
$3.28
1-Week Range:
$3.03
$3.848
52-Week Range:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.13 | 975.31M | 548.10M | 69.50M | -137.90M | 0.2303 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Alvotech price target lowered to $4 from $8 at Deutsche Bank - TipRanks
Barclays Lowers Price Target for Alvotech (ALVO) to $4.00, Maint - GuruFocus
UBS cuts Alvotech stock price target on delayed biosimilar launches - Investing.com UK
Alvotech (ALVO) Maintains 'Buy' Rating with Lowered Price Target by UBS | ALVO Stock News - GuruFocus
UBS Group Cuts Alvotech (NASDAQ:ALVO) Price Target to $6.00 - MarketBeat
Barclays Has Lowered Expectations for Alvotech (NASDAQ:ALVO) Stock Price - MarketBeat
UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating - marketscreener.com
Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating - marketscreener.com
Alvotech: Regulatory Setbacks Priced In, Biosimilar Strength Supports Buy Rating Despite Lowered Target - TipRanks
Alvotech SA stock hits 52-week low at $3.42 amid challenging year - Investing.com Canada
Barclays lowers Alvotech stock price target to $4 on approval timing - Investing.com India
Alvotech (NASDAQ:ALVO) Trading Down 5.1%Here's What Happened - MarketBeat
Alvotech price target lowered to $4 from $5 at Barclays - TipRanks
Northland Securities Weighs in on Alvotech FY2026 Earnings - MarketBeat
Operating cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Free cash flow per share of Alvotech – NASDAQ:ALVOW - TradingView
Analyst Calls: Can Alvotech Equity Warrant maintain its current growth rateWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Alvotech Stock Faces Market Cap Decline Amid Biotech Sector Pressures in Early 2026 - AD HOC NEWS
Alvotech (NASDAQ:ALVO) Upgraded by Zacks Research to Hold Rating - MarketBeat
Alvotech stock advances on biosimilar approvals and capacity expansion amid strong biotech momentum - AD HOC NEWS
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative? - Yahoo Finance
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles By Investing.com - Investing.com Canada
Alvotech (ALVO) TTM Profitability Challenged By Q4 US$108.5 Million Net Loss - simplywall.st
Alvotech outlines 2026 revenue target of $650M-$700M while expanding global biosimilar launches - MSN
Alvotech (NASDAQ:ALVO) Hits New 1-Year LowShould You Sell? - MarketBeat
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles - Investing.com
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast By Investing.com - Investing.com Australia
ALVO: 2025 revenue rose 21% to $593M; 2026 guidance set at $650–$700M with strong pipeline momentum - TradingView
Alvotech Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast - Investing.com
Alvotech 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-03-19 - Seeking Alpha
Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands - TipRanks
Alvotech (NASDAQ: ALVO) turns profit as 2025 revenue rises 21% and sets 2026 growth targets - Stock Titan
Alvotech earnings beat by $0.11, revenue topped estimates - Investing.com India
Alvotech earnings beat by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Alvotech Q4 Revenue Increases; 2026 Revenue Guidance Issued - marketscreener.com
Alvotech Provides Updates on Launch & Regulatory Plans for Golimumab, High Dose Aflibercept, Vedolizumab and Pembrolizumab Biosimilars - Pearce IP
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance - ChartMill
Alvotech's Guidance Hike Sets Higher Bar for 2026 Growth Execution - Bitget
ALVOTECH ($ALVO) Releases Q4 2025 Earnings - Quiver Quantitative
Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments - Quiver Quantitative
Alvotech Q4 2025 and Full Year 2025 Financial Results - Caledonian Record
Alvotech expects four U.S. biosimilar approvals by late 2026 - Stock Titan
Alvotech’s fourth quarter results need to support the bearish outlook in order to shift the prevailing story - Bitget
Earnings Scheduled For March 18, 2026 - Benzinga
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Alvotech's Q4 Report: Regulatory Concerns for AVT05 Diminish Impact of Revenue Outperformance - Bitget
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):